Patrick E Roberts

US Patent:

20070010384, Jan 11, 2007

Filed:

May 26, 2006

Appl. No.:

11/441469

Inventors:

Patrick Roberts - Keller TX, US

International Classification:

A63B 21/00
A63B 26/00
A63B 23/00
A63B 71/00

US Classification:

482140000, 482092000, 482148000, 482141000

Abstract:

A wheel exercise apparatus comprises a single wheel, preferably air-inflated, that has an axle passing through it. Foot rests for receiving the feet of a user are connected to the opposing ends of the axle. Each foot rest has a toe cup. The foot rests have cable attachment points for optionally connecting a weight sled to the apparatus or connecting foot plates having fixed heel rests. The foot plates allow exercises where the the user's body is facing upward. One method of using the apparatus includes the steps of the user kneeling; placing a wheel exercise apparatus behind the user; placing the toes of the user in the toe cups of the wheel exercise apparatus; stretching out the body of the user away from the wheel exercise apparatus; and, walking forward with the hands while balancing II the body on the wheel exercise apparatus.

US Patent:

20220175780, Jun 9, 2022

Filed:

Aug 16, 2021

Appl. No.:

17/403577

Inventors:

- Research Triangle Park NC, US
John E. Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Jessica A. Sorrentino - Durham NC, US

International Classification:

A61K 31/519
A61K 31/4745
A61K 31/5375
A61K 31/5377
A61K 31/695

Abstract:

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

US Patent:

20210267986, Sep 2, 2021

Filed:

May 7, 2021

Appl. No.:

17/315011

Inventors:

- Research Triangle Park NC, US
Patrick Joseph Roberts - Durham NC, US
Jay Copeland Strum - Hillsborough NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
A61K 31/357
A61K 45/06
A61P 35/04

Abstract:

The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.

US Patent:

20210077498, Mar 18, 2021

Filed:

Nov 23, 2020

Appl. No.:

17/102311

Inventors:

- Research Triangle Park NC, US
John Emerson Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Francis Xavier Tavares - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
A61K 45/06
C07D 487/20
A61K 38/18
A61K 38/19
A61K 38/20
A61K 31/202
A61K 31/702
A61K 31/519
A61N 5/10

Abstract:

This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.

US Patent:

20210030758, Feb 4, 2021

Filed:

Oct 9, 2020

Appl. No.:

17/067549

Inventors:

- Research Triangle Park NC, US
Daniel M. Freed - Cary NC, US
Jessica A. Sorrentino - Durham NC, US
John E. Bisi - Apex NC, US
Andrew Beelen - Research Triangle Park NC, US
Patrick Joseph Roberts - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/519
A61P 35/00
A61K 31/4439
A61K 31/506
A61K 31/4184
A61K 31/4523
A61K 31/4545
A61K 31/4745
A61K 31/5377
A61K 31/517
A61K 31/685

Abstract:

Methods and compositions are described to treat a cancer having a specific oncogenic driving mutation by administering a CDK4/6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides advantageous or synergistic inhibitory activity, delays acquired resistance to the additional kinase inhibitor, and/or extends the efficacy of the kinase inhibitor.

US Patent:

20200345743, Nov 5, 2020

Filed:

Jul 10, 2020

Appl. No.:

16/926035

Inventors:

- Research Triangle Park NC, US
John Emerson Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Francis Xavier Tavares - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
C07D 487/14
A61K 31/5377
A61K 51/04
A61K 31/529
A61K 47/68
A61K 47/54

Abstract:

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.

US Patent:

20200022983, Jan 23, 2020

Filed:

Sep 16, 2019

Appl. No.:

16/572418

Inventors:

- Research Triangle Park NC, US
John E. Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Jessica A. Sorrentino - Durham NC, US

International Classification:

A61K 31/519
A61K 31/4745
A61K 31/5375
A61K 31/5377
A61K 31/695

Abstract:

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

US Patent:

20190321370, Oct 24, 2019

Filed:

Jun 5, 2019

Appl. No.:

16/432244

Inventors:

- Research Triangle Park NC, US
Ann Y. Lai - Cary NC, US
Jay C. Strum - Hillsborough NC, US
Patrick Joseph Roberts - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/519
A61P 35/00
A61K 31/365
A61K 33/243
A61K 38/17

Abstract:

The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.